TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke
Ključne riječi
Sažetak
Opis
Tryptophan (TRP), an essential aminoacid, is metabolized in the serotonin (5-HT) or in the kynurenine (KYN) pathway. Serotonin is catabolized to 5-HIAA (5-hydroxyindole amino acid) by monoamine oxidase A (MAOA). The TRP to KYN transformation is regulated by indoleamine 2,3-dioxygenase (IDO).
The primary objective was the measurements of serotonin and kynurenine pathways parameters which were performed in blood and urine samples using different HPLC techniques and of serotonin transporters and receptors which were determined in blood platelets. The results in patients were compared to those measured in controls matched for age, gender, tobacco consumption and season of inclusion.
The secondary objective was to evaluate the potential relationships between these 5-HT and Kyn pathways biomarkers concentrations, MAOA and IDO enzymatic activations and clinical outcome and criteria.
Datumi
| Posljednja provjera: | 10/31/2016 |
| Prvo podneseno: | 09/15/2016 |
| Predviđena prijava predata: | 11/13/2016 |
| Prvo objavljeno: | 11/14/2016 |
| Zadnje ažuriranje poslato: | 11/15/2016 |
| Posljednje ažuriranje objavljeno: | 11/16/2016 |
| Stvarni datum početka studija: | 09/30/2012 |
| Procijenjeni datum primarnog završetka: | 10/31/2014 |
| Predviđeni datum završetka studije: | 04/30/2016 |
Stanje ili bolest
Intervencija / liječenje
Other: Patients presenting cerebral infarction
Biological: blood and urines sampling
Procedure: Patients presenting cerebral infarction
Faza
Grupe ruku
| Arm | Intervencija / liječenje |
|---|---|
| Experimental: Patients presenting cerebral infarction no intervention of health product administration, | Other: Patients presenting cerebral infarction patients characteristics, history, clinical signs chronology and usual medical care by the emergency units, cerebral infarction area |
| Other: Historical controls no intervention of health product administration, patients characteristics, history, matched with patients for age, gender, tobacco consumption and season of inclusion, free of neurologic or psychiatric disease or psychotropic medications or medications known to impact on serotonin |
Kriteriji prihvatljivosti
| Uzrast podoban za studiranje | 18 Years To 18 Years |
| Polovi podobni za studiranje | All |
| Prihvaća zdrave volontere | Da |
| Kriterijumi | Study population : patients who had positive MRI diagnosis of cerebral infarction less than 4.30 hours after the clinical onset. Experimental group : Inclusion Criteria: - Age ≥ 18 ans - Cerebral infarction with a medical care to emergencies less than 4.30 hours after the symptoms onset. - Written informed consent signed by the patient, or by a trusted person then by the patient himself if permitted by his condition. Exclusion Criteria: - Cerebral infarction with a medical care to emergencies more than 4.30 hours after the symptoms onset. - Patient with subarachnoid haemorrhage, cerebral hematoma. - Pregnant woman - Patient under guardianship or trusteeship, or safeguard justice. Control group : - Matching criteria for age, gender, tobacco smoking, inclusion season |
Ishod
Primarne mjere ishoda
1. Measure of serotonin pathway parameters concentrations in blood and urine samples [Day 1]
2. Measure of serotonin pathway parameters in blood samples [Day 1]
3. Measure of serotonin pathway parameters in blood and urine samples [Day 2]
4. Measure of serotonin pathway parameters in blood and urine samples [Month 3]
5. Measure of kynurenin pathway parameters in blood samples [Day 1]
6. Measure of kynurenin pathway parameters in blood samples [Day 2]
7. Measure of kynurenin pathway parameters in blood samples [Month 3]
Ostale mjere ishoda
1. Patient characteristics, history, clinical signs chronology [Day 1]
2. Patient characteristics, clinical signs [Day 2]
3. Patient characteristics, clinical signs [Month 3]
4. Depression scale [Day 2]
5. Impulsivity scale [Day 2]
